Company Overview
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $129.66B (+10.1% YoY); net profit $1.19B.
- Trailing 12 Months Year-on-year growth — revenue +23.5%, earnings -4.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.5%, profit CAGR 2.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.51% |
| 1 Year: | 23.50% |
Compounded Profit Growth
| 5 Years: | 1.99% |
| 1 Year: | -4.60% |
Stock Price Performance
| 1 Year: | +81.41% |
| 6 Months: | +48.02% |
| 3 Months: | +105.69% |
| 1 Month: | +10.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)71.63 · Overbought
P/E of 43.41 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HUM Humana Inc. SPX | 406.77 | 43.41 | $48.84B | 0.93% | 8.30% | 6.28% | 9.51% | 1.99% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.33B | 13.83B | 13.73B | 13.36B | 13.36B | 13.80B | 14.01B | 13.69B | 12.88B | 13.76B | 13.53B | 13.28B | 13.19B | 14.28B | 14.26B | 14.21B | 14.17B | 16.11B | 16.25B | 16.24B | 16.30B | 18.93B | 19.08B | 20.07B | 20.67B | 20.64B | 20.70B | 23.97B | 23.66B | 22.80B | 26.74B | 26.75B | 26.42B | 29.61B | 29.54B | 29.40B | 32.11B | 32.39B | 32.65B | 39.65B |
| Operating Income | - | 790.00M | 573.00M | 695.00M | - | 547.00M | 683.00M | 949.00M | - | 1.74B | 1.10B | 858.00M | - | 760.00M | 862.00M | 961.00M | - | 847.00M | 1.11B | 868.00M | - | 1.07B | 2.44B | 1.82B | 1.22B | 1.24B | 628.00M | 1.29B | 1.22B | 1.17B | 1.72B | 1.44B | 1.21B | 1.24B | 1.14B | 728.00M | 2.01B | 1.10B | 400.00M | 1.75B |
| Net Income | 145.00M | 430.00M | 431.00M | 314.00M | 101.00M | 254.00M | 311.00M | 450.00M | -401.00M | 1.11B | 650.00M | 499.00M | 184.00M | 491.00M | 193.00M | 644.00M | 355.00M | 566.00M | 940.00M | 689.00M | 512.00M | 473.00M | 1.83B | 1.34B | 828.00M | 588.00M | 1.53B | 930.00M | 696.00M | 1.20B | 1.24B | 959.00M | 832.00M | 741.00M | 679.00M | 480.00M | 1.24B | 545.00M | 195.00M | 1.19B |
| Diluted EPS | 0.94 | 2.82 | 2.85 | 2.09 | 0.67 | 1.68 | 2.06 | 2.98 | -2.68 | 7.49 | 4.46 | 3.44 | 1.29 | 3.53 | 1.39 | 4.65 | 2.58 | 4.16 | 6.94 | 5.14 | 3.84 | 3.56 | 13.75 | 10.05 | 6.39 | 4.55 | 11.84 | 7.29 | 5.48 | 9.39 | 9.87 | 7.66 | 6.71 | 6.11 | 5.62 | 3.98 | 10.30 | 4.51 | 1.62 | 9.83 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.29B | 28.95B | 30.74B | 33.60B | 36.83B | 39.13B | 41.31B | 48.50B | 54.29B | 54.38B | 53.77B | 56.91B | 64.89B | 77.16B | 83.06B | 92.87B | 106.37B | 117.76B | 129.66B |
| Operating Income | 1.36B | 1.07B | 1.71B | 1.85B | 2.34B | 2.02B | 2.06B | 2.36B | 2.35B | 1.74B | 4.26B | 3.10B | 3.19B | 4.99B | 3.15B | 3.80B | 4.01B | 2.56B | 2.70B |
| Net Income | 833.68M | 647.15M | 1.04B | 1.10B | 1.42B | 1.22B | 1.23B | 1.15B | 1.28B | 614.00M | 2.45B | 1.68B | 2.71B | 3.37B | 2.93B | 2.81B | 2.49B | 1.21B | 1.19B |
| Diluted EPS | 4.91 | 3.83 | 6.15 | 6.47 | 8.46 | 7.47 | 7.73 | 7.36 | 8.44 | 4.07 | 16.81 | 12.16 | 20.10 | 25.31 | 22.67 | 22.08 | 20.00 | 9.98 | 9.84 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 13.04B | 14.15B | 16.10B | 17.71B | 19.98B | 20.73B | 23.53B | 24.68B | 25.40B | 27.18B | 25.41B | 29.07B | 34.97B | 44.36B | 43.05B | 47.06B | 46.48B | 48.91B |
| Total Equity | 3.05B | 4.03B | 4.46B | 5.78B | 6.92B | 8.06B | 8.85B | 9.32B | 9.65B | 10.35B | 10.69B | 9.84B | 10.16B | 12.04B | 13.73B | 16.08B | 15.31B | 16.26B | 16.38B | 17.66B |
| Cash & Equivalents | 1.74B | 2.04B | 1.97B | 1.61B | 1.67B | 1.38B | 1.31B | 1.14B | 1.94B | 2.57B | 3.88B | 4.04B | 2.34B | 4.05B | 4.67B | 3.39B | 5.06B | 4.69B | 2.22B | 4.20B |
| Long Term Debt | - | - | 1.94B | 1.68B | 1.67B | 1.66B | 2.61B | 2.60B | 3.83B | 3.79B | 3.79B | 4.77B | 4.38B | 4.97B | 6.06B | 10.54B | 9.03B | 10.21B | 11.14B | 12.37B |
| Total Liabilities | - | - | 8.58B | 8.38B | 9.18B | 9.64B | 11.13B | 11.42B | 13.88B | 14.33B | 14.71B | 17.34B | 15.25B | 17.04B | 21.24B | 28.25B | 27.68B | 30.75B | 30.03B | 31.17B |
| Current Liabilities | - | - | 5.18B | 5.26B | 5.74B | 6.06B | 6.38B | 6.32B | 7.47B | 8.15B | 7.82B | 9.41B | 10.08B | 10.93B | 13.39B | 15.33B | 17.18B | 18.87B | 16.94B | 16.35B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.22B | 982.31M | 1.42B | 2.24B | 2.08B | 1.92B | 1.72B | 1.62B | 868.00M | 1.94B | 4.05B | 2.17B | 5.28B | 5.64B | 2.26B | 4.59B | 3.98B | 2.97B | 921.00M |
| Investing Cash Flow | -1.85B | -498.32M | -1.86B | -1.81B | -1.36B | -1.97B | -1.18B | -63.00M | 320.00M | -1.36B | -2.94B | -3.09B | -1.28B | -3.06B | -6.56B | -1.01B | -3.49B | -2.95B | 2.27B |
| Financing Cash Flow | 921.28M | -554.02M | 80.00M | -371.00M | -1.02B | -29.00M | -702.00M | -758.00M | -552.00M | 732.00M | -945.00M | -785.00M | -2.29B | -1.96B | 3.02B | -1.91B | -856.00M | -2.49B | -1.22B |
| Capital Expenditure | -239.24M | -261.57M | -185.00M | -222.00M | -346.00M | -410.00M | -441.00M | -528.00M | -523.00M | -527.00M | -524.00M | -612.00M | -736.00M | -964.00M | -1.34B | -1.14B | -1.00B | -575.00M | -546.00M |
| Free Cash Flow | 985.02M | 720.74M | 1.24B | 2.02B | 1.73B | 1.51B | 1.27B | 1.09B | 345.00M | 1.41B | 3.53B | 1.56B | 4.55B | 4.67B | 920.00M | 3.45B | 2.98B | 2.39B | 375.00M |
| Share Buybacks | 27.41M | 106.07M | 23.00M | 108.00M | 541.00M | 518.00M | 531.00M | 872.00M | 385.00M | 104.00M | 3.37B | 1.09B | 1.07B | 1.82B | 79.00M | 2.10B | 1.57B | 817.00M | 151.00M |
| Dividends Paid | - | - | 0 | 0 | 82.00M | 165.00M | 168.00M | 172.00M | 172.00M | 177.00M | 220.00M | 265.00M | 291.00M | 323.00M | 354.00M | 392.00M | 431.00M | 431.00M | 430.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 5.4% | 3.7% | 5.6% | 5.5% | 6.4% | 5.2% | 5.0% | 4.9% | 4.3% | 3.2% | 7.9% | 5.4% | 4.9% | 6.5% | 3.8% | 4.1% | 3.8% | 2.2% | 2.1% |
| Net Margin % | 3.3% | 2.2% | 3.4% | 3.3% | 3.9% | 3.1% | 3.0% | 2.4% | 2.4% | 1.1% | 4.6% | 3.0% | 4.2% | 4.4% | 3.5% | 3.0% | 2.3% | 1.0% | 0.9% |
| ROE % | 20.7% | 14.5% | 18.0% | 15.9% | 17.6% | 13.8% | 13.2% | 11.9% | 12.3% | 5.7% | 24.9% | 16.6% | 22.5% | 24.5% | 18.2% | 18.3% | 15.3% | 7.4% | 6.7% |
| ROCE % | - | 13.7% | 19.2% | 17.9% | 20.1% | 14.8% | 14.3% | 14.7% | 14.2% | 9.9% | 24.0% | 20.2% | 17.6% | 23.1% | 10.8% | 14.7% | 14.2% | 8.7% | 8.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Dodge & Cox Inc. | 9.48% | 11.38M | $4.46B |
| 2 | Blackrock Inc. | 8.49% | 10.20M | $3.99B |
| 3 | Vanguard Capital Management LLC | 6.53% | 7.84M | $3.07B |
| 4 | Vanguard Portfolio Management LLC | 4.84% | 5.81M | $2.27B |
| 5 | Pzena Investment Management LLC | 4.56% | 5.47M | $2.14B |
| 6 | State Street Corporation | 4.54% | 5.45M | $2.14B |
| 7 | Massachusetts Financial Services Co. | 3.73% | 4.48M | $1.76B |
| 8 | Sessa Capital IM, L.P. | 3.10% | 3.73M | $1.46B |
| 9 | Geode Capital Management, LLC | 2.77% | 3.33M | $1.30B |
| 10 | JPMORGAN CHASE & CO | 2.53% | 3.03M | $1.19B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HUM
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTFByOWp3STJseXY1cnJaNWtsN0JiRWlDM2tBTDJ1ekpkS2xGdDEyTXR1MzFKU2FOZ1RoTGJYbmNYUWhJZWtUeUo5RkJtQ01XRjA?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <font…
Humana (HUM) Stock Stays Near Fair Value As Earnings And Growth Pull Apart - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOMDB6aXBQMFJVNlRkRERtTVM1dmNOd0xqR190Z2paUS1oc2d5aUpLc2xWZS1USVl3UGE3QWVHYXUxU3RqMzhGaGVINnF0RmpkMjZacUVKMHFSS09veGVFSjJGQXZwRGFKdDJFRFE0UWZkUVM1S1JRbjlCdXVFUGFBU2ZuTjdDR1YxTUp0Rk…
HUM Maintained by TD Cowen -- Price Target Raised to $350 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQM19TdkNvMmtab2xzRE53WGxFNTh6eUgybHVDTThpN0w3QzBoXzhIcXViOUxiUXNSVHFxOGpkWGx1aG9kYkUyOWZJQkt2TEJUV2ZQSHhlR3Y4QVY0b2ZHbWw2dkJac1J2MjJWWEZoSFJwM0NGVjdua3hocUREMUJSWXpBTkU4ZGluZTNYNG…
Humana (NYSE:HUM) Price Target Raised to $415.00 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOcUNnUGNNVklWWFJGOXRicTQ5b19JSUtSc3dXeFViYkhLMHlkXzVzWmVPOVE4MnV3Y3hhZzBDT2F5b3JVak5CM1Z5dE1JQVFMQXk0U1J3UHh4WVNWT3o4S2tDX092S295LTJvQVo2NHF3Y0NlOUZVc0hLbGI5VGVndVpBdElsWVNkeVBLRG…
Humana (HUM) Stock Looks Fully Priced On Illinois Medicaid Win - Sahm
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQZUF5SzRFSkJ0SzVDZFRfU2RiX1czY2xQamQ2QVQtMEZYZkZQbU02MmxiZ0RWUFg4TlNYcW5rQ2FjUnN1Q0dkVFZaLV9zTUdVbjRPRXZwWl9HNHJqcEk3ZEN0aEEzYmZFZVFDbHl0bkcyUU1hdFBwT3l6MEZua283NVJnMWFMMnZ0cmdHYm…
Humana pops as Wells Fargo upgrades on moderating cost trends (HUM:NYSE) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQNDBDbXkyMW8wcThsSENjOENwU0VDcnoxZ3QzX2IyUTZDT1haMlNZY011U2E0ZGZDcDFOVTFod1Jtc1REVURMN0RQNVJIbEdzNmJaN1Y1aFNhbThwX2E5V253Uk1IUlpVWWoxNW5XS1N6VFlSQVV5TmcyMG9UajU4a1d5ZGt3SjUwV19pSW…
HUM — Frequently Asked Questions
What is the current share price of Humana Inc. (HUM)?
As of 2026-07-14 21:23 PDT, Humana Inc. (HUM) trades at $406.77 on NYSE. Its 52-week range is $162.46 to $409.42.
What is the market capitalisation of HUM?
Humana Inc. (HUM) has a market capitalisation of $48.84B on NYSE.
What is the P/E ratio of HUM?
HUM trades at a trailing price-to-earnings (P/E) ratio of 43.41. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.45.
Does HUM pay a dividend?
Humana Inc. (HUM) currently offers a dividend yield of 0.93%.
What is the return on equity (ROE) of HUM?
HUM has a return on equity (ROE) of 6.28%. Its return on capital employed (ROCE) is 8.30%.
Is HUM a good stock to buy?
This page provides a data-driven analysis of Humana Inc. (HUM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.